Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Summary

This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.

Timeline

Start

2015-05

Primary completion

2016-11

Completion

2016-11

Outcome

Met primary endpoint

registry analysis (superiority test); RVL-1201 vs Vehicle Ophthalmic Solution; p <0.0001; ANCOVA NCT02436759 ↗

Drugs

Indications